William Blair Has Strong Estimate for IPSC FY2024 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - William Blair lifted their FY2024 earnings estimates for Century Therapeutics in a research report issued on Tuesday, November 5th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($1.64) per share for the year, up from their previous forecast of ($1.88). The consensus estimate for Century Therapeutics' current full-year earnings is ($1.80) per share. William Blair also issued estimates for Century Therapeutics' Q4 2024 earnings at ($0.44) EPS, Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS and FY2025 earnings at ($1.81) EPS.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company had revenue of $0.79 million for the quarter, compared to analysts' expectations of $0.47 million. Century Therapeutics had a negative return on equity of 60.60% and a negative net margin of 6,434.23%. During the same quarter in the previous year, the firm posted ($0.55) earnings per share.

A number of other research firms have also weighed in on IPSC. Chardan Capital lowered their price target on shares of Century Therapeutics from $17.00 to $11.00 and set a "buy" rating for the company in a report on Thursday. Rodman & Renshaw began coverage on Century Therapeutics in a research report on Thursday, August 8th. They set a "buy" rating and a $6.00 target price on the stock. Finally, HC Wainwright reduced their price target on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Century Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $11.60.

Century Therapeutics Price Performance

NASDAQ IPSC traded down $0.02 on Friday, reaching $1.44. The company had a trading volume of 327,206 shares, compared to its average volume of 261,880. Century Therapeutics has a 1 year low of $1.14 and a 1 year high of $5.51. The firm has a 50-day moving average of $1.52 and a 200-day moving average of $2.23. The firm has a market capitalization of $121.99 million, a PE ratio of -0.79 and a beta of 1.41.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in Century Therapeutics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 165,500 shares of the company's stock valued at $422,000 after purchasing an additional 9,500 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Century Therapeutics in the first quarter worth about $47,000. Vanguard Group Inc. grew its holdings in shares of Century Therapeutics by 1.2% during the first quarter. Vanguard Group Inc. now owns 1,138,653 shares of the company's stock valued at $4,760,000 after purchasing an additional 14,000 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Century Therapeutics during the third quarter valued at approximately $27,000. Finally, Rhumbline Advisers raised its position in shares of Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company's stock worth $134,000 after purchasing an additional 18,828 shares during the period. Institutional investors and hedge funds own 50.20% of the company's stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.